Samalizumab(TD-HW741016) is a research-grade recombinant antibody targetingCD200. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.
Species reactivity
Human
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species
Humanized
Isotype
IgG2-G4-kappa
Clonality
Monoclonal
Target
OX-2 membrane glycoprotein, MOX2, MOX1, CD200
Endotoxin level
Please contact the lab for this information.
Purity
>95% purity as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P41217
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate Names
ALXN6000, Anti-CD200, hB7V3V2G2G4, 1073059-33-2
Background
Samalizumab (ALXN 6000) is a humanized monoclonal antibody that specifically binds to CD200 and blocks its ligation to the CD200 receptor (CD200R). Samalizumab can be used for multiple myeloma and B-cell chronic lymphocytic leukemia research.• Homeodomain proteins Mox1 and Mox2 associate with Pax1 and Pax3 transcription factors., PMID:11423130• Mox2 is a component of the genetic hierarchy controlling limb muscle development., PMID:10403250
Caption
Detects CD200 in indirect ELISAs. | SDS-PAGE for Research Grade Samalizumab.
Note
For research use only. Not suitable for clinical or therapeutic use.